AstraZeneca files New Drug Application for Brilinta
19th Nov 2009 07:39
Anglo-Swiss drug giant AstraZeneca has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its Brilinta blood cot prevention treatment. The submission for Brilinta, currently known as ticagrelor, follows successful trials and a phase III study that found the drug
Read moreSector movers: Lonmin lifts miners
16th Nov 2009 12:13
A strong performance from the FTSE 100-listed platinum miner Lonmin is driving the mining sector higher. Lonmin reported a pre-tax loss of $272m for the period, compared with a profit of $779m over the same period the previous year, as revenues fell to $1,062m from $2,231m and said it will not pay
Read moreNew Travis chairman buys
30th Oct 2009 16:31
Robert Walker, the chairman-designate of Travis Perkins, has bought his first shares in the builders' merchant. Walker was appointed to the Travis Perkins board on 30 September 2009 and he is due to take over as chairman from Tim Stevenson in May 2010. Walker has bought a total of 25,000 shares at
Read moreFriday tips round-up: AstraZeneca, Kazakhmys, Standard Life
30th Oct 2009 06:11
AstraZeneca posted a sparkling set of third-quarter results on Thursday, sending analysts scurrying away to upgrade their numbers. Pre-tax profits rocketed by 24pc, on revenues up 5pc. On closer inspection, however, the results were flattered by a series of ?one-off gains. The Telegraph recommended
Read moreLondon close: Shares end near session high
29th Oct 2009 16:23
London's top stocks closed near its session high on news that the US economy grew faster than expected in the third quarter. Traders loved news that the US economy grew 3.5% annually in the last quarter, more than expected and the fastest rate of increase in two years. Part-nationalised bank Lloyd
Read moreComment: Astra's stars will wane
29th Oct 2009 15:29
AstraZeneca impressed the market with better-than-expected third quarter sales and lifted its earnings estimates for the full year, but beyond that the Anglo-Swedish drugmaker could be set for a severe comedown. Sales over the quarter climbed by 5% from the same period a year ago to $8.2bn, lifting
Read moreFTSE 100 movers: Banks bounce back
29th Oct 2009 15:10
Shares in Lloyds Banking, which is in advanced discussions with UK authorities regarding alternatives to entering the state insurance scheme for toxic debt, are soaring. The lender is considering raising cash via an underwritten rights issue and debt swap. Fellow part-nationalised lender Royal Bank
Read moreLondon afternoon: Blue chips track US advance
29th Oct 2009 14:55
America's return to growth in the third quarter, stronger UK banks and a better mining sector have propelled London far into the blue Thursday. Traders loved news that the US economy grew 3.5% annually in the last quarter, more than expected and the fastest rate of increase in two years. Part-nati
Read moreAstraZeneca delivers strong Q3 earnings
29th Oct 2009 11:03
AstraZeneca's third quarter earnings beat market forecasts with a 27% hike in profit at constant exchange rates (CER), prompting the Anglo-Swedish drug giant to lift full-year targets. Core earnings jumped to $1.68 a share during the three months ended 30 September, up 28% at actual exchange rates
Read moreLondon close: Triple-digit losses for FTSE 100
28th Oct 2009 16:26
A poor performance from mining and financial stocks ensured that Footsie ended with triple-digit losses. Insurer Prudential, which saw a surge in US business but posted a fall in UK sales, was a heavy faller. The Pru lifted group-wide retail sales by 10% to £699m in the third quarter thanks largel
Read moreThursday preview: Shell, Astra, CSR
28th Oct 2009 14:28
There should be no shortage of corporate announcements on Thursday with third quarter updates expected from AstraZeneca, CSR, Kazakhmys, Royal Dutch Shell, Standard Life and Virgin Media. Results from oil giant Royal Dutch Shell follow hot on the heels of much better than expected figures from long
Read moreLondon afternoon: Stocks steady at lower levels
28th Oct 2009 14:10
Miners and financials remain a dead weight around Footsie's neck, but elsewhere, leading shares are slowly beginning to claw back losses. Prudential, which saw a surge in US business but posted a fall in UK sales, is still among the heaviest fallers. The Pru lifted group-wide retail sales by 10% to
Read moreLondon midday: Miners join financials on the slide
28th Oct 2009 12:05
Miners have joined financial stocks in the dog house as the Footsie dives below 5200 and threatens to carry on going to sub-5100 levels. With metal prices in retreat miners such as Xstrata, Lonmin and Kazakhmys have muscled aside insurer Prudential in the race to be worst performing Footsie stock.
Read moreLondon open: Shares start down
28th Oct 2009 08:21
London's blue chips have opened lower as investors consider a slew of big corporate announcements and rumours surrounding the British banking sector. The European Commission is expected to approve plans to break up and sell Northern Rock, according to press reports. The Independent is quoting a Br
Read moreZactima blow for AstraZeneca
28th Oct 2009 07:52
Drugs giant AstraZeneca has yanked the US and European regulatory submissions for its lung cancer treatment Zactima. The applications were submitted in June but after further analysis of test results no overall survival advantage was discerned when chemotherapy treatment was augmented by a dose of
Read more